The Diamond laboratory is focused on the development of novel targeted therapies for triple-negative breast cancer. Their focus is on cell cycle targeting agents and combination immunotherapy. The lab has a special interest in predictive biomarker development and conducting correlative biological assays for early phase clinical trials.
Diamond JR, Bastos BR, Hansen RJ, Gustafson DL, Eckhardt SG, Kwak E, Pandya SS, Fletcher GC, Pitts TM, Kulikowski GN, Morrow M, Arnott J, Bray MR, Sidor CF, Messersmith WA, Shapiro GI. Phase I safety, pharmacokinetic and pharmacodynamic study of ENMD-2076, a novel angiogenic and aurora kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2011:17;849-860 (PMID: 21131552).
Diamond JR, Eckhardt SG, Tan AC, Newton TP, Selby HM, Brunkow KL, Kachaeva MI, Varella-Garcia M, Pitts TM, Bray MR, Fletcher GC, Tentler JJ. Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models. Clin Cancer Res 2013: 19;291-303 (PMID: 23136197) (Cover Feature).
Tentler JJ, Ionkina A, Tan AC, Newton TP, Pitts TM, Glogowska MJ, Kabos P, Sartorius CA, Sullivan KD, Espinosa JM, Eckhardt SG, Diamond JR. p53 family members regulate phenotypic response to Aurora kinase A inhibition in triple-negative breast cancer. Mol Cancer Ther 2015:14;1117-1129 (PMID: 25758253).
Ryall KA, Kim J, Klauck PJ, Shin J, Yoo M, Ionkina A, Pitts TM, Tentler JJ,Diamond JR, Eckhardt S, Heasley LE, Kang J, Tan AC. An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer. BMC Genomics 2015:16 Suppl 12; S2 (PMID: 26681397).
Jennifer R. Diamond, MD
John J. Tentler, PhD
Professional Research Assistant